GlassScriptPhysician profile
Vijaykumar C Patel
NPI 1972619294
$4,029.95
in general payments reported to CMS, 2019-2025
33 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $288 · 2021: $895 · 2022: $669 · 2023: $407 · 2024: $626 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $782.16 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $497.58 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $435.64 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $358.15 | 2021-2024 | Xarelto, Spravato |
| Pfizer INC. | $314.55 | 2019-2025 | |
| Amgen INC. | $247.31 | 2019-2025 | Repatha, Otezla, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $177.78 | 2022-2024 | |
| Amarin Pharma, INC. | $176.51 | 2019 | |
| Novo Nordisk INC | $144.22 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $140.95 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.55 | 2021 | |
| Travere Therapeutics, INC. | $86.73 | 2023-2024 | |
| Horizon Therapeutics Plc | $71.29 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $68.29 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $56.54 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.97 | 2021-2022 | |
| Medtronic Minimed, INC. | $32.78 | 2019-2020 | |
| Biotronik Nro, INC. | $26.30 | 2024 | Prospera |
| Eisai INC. | $25.68 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.99 | 2023 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $21.07 | 2024 | Aptima |
| Arbor Pharmaceuticals, INC. | $20.27 | 2020 | |
| Insulet Corporation | $19.88 | 2019 | |
| Astellas Pharma US INC | $19.11 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $17.78 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $16.47 | 2020 | |
| Exact Sciences Corporation | $16.32 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $15.67 | 2020 | |
| Esperion Therapeutics, INC. | $15.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2025 | Zoryve |
| Echosens North America, INC. | $13.86 | 2022 | |
| Smith+Nephew, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaykumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.